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Abstract
Studies of widely diverse species of a protein are a powerful tool to gain
information on the structure and function of the protein. We investigated the
response of human, pig, shark and killifish cystic fibrosis trans-membrane
conductance regulator (CFTR) to specific inhibitors of the channel: CFTRinh172, GlyH-101, and glibenclamide. In several expression systems, including
isolated perfusions of the rectal gland, primary cell cultures of rectal gland tubules
and oocyte expression, we observed fundamental differences in the sensitivity to
inhibition by these CFTR blockers. We used primarily two-electrode voltage
clamping of cRNA microinjected Xenopus laevis oocytes. In oocyte studies,
shark CFTR was insensitive to CFTRinh-172 (maximum inhibition 8 ± 1.4% at
20µM), pCFTR was insensitive to Glibenclamide (maximum inhibition 12.8 ±
4.2% at 200µM), and all species were sensitive to GlyH-101 (maximum inhibition
with pCFTR of 80.2 ± 3.6% at 20µM). Shark CFTR was completely insensitive to
inhibition by CFTRinh-172 in short circuit current experiments (2.5 ± 0.15 %
inhibition of chloride secretion) compared to inhibition with GlyH-101 (56.5 ±
6.56 % inhibition of chloride secretion). Perfusion studies confirmed these results.
These experiments demonstrate a profound difference in the sensitivity of
different CFTR species to inhibition by CFTR blockers. However, the amino acid
residues that have been proposed by site directed mutagenesis studies to be
responsible for inhibitor binding are uniformly conserved in all four isoforms
studied. Therefore, the differences cannot be explained by simply targeting one
amino acid for site-directed mutagenesis. Rather, the potency of the inhibitory
actions of CFTRinh-172, Gly-H101 and glibenclamide on the CFTR molecule is
dictated by the local environment and the three dimensional structure of residues
that form the vestibule and the chloride pore.
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oocyte experiments and for their work with human and shark CFTR full inhibitor
experiments and for their immense experimental and written contributions to this
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Christine Chaplin and Catherine Kelley for their help. Thank you to my thesis
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Introduction
Overview of Cystic Fibrosis
Cystic fibrosis (CF) is a prototypical example of a simple mutation in a
single gene that ultimately causes a complex disease. (1-2) CF is caused by
mutations in the cystic fibrosis trans-membrane conductance regulator (CFTR)
protein, a chloride channel and regulatory protein found in exocrine glandular
tissues. As a result, CF is a disorder of exocrine function involving multiple organ
systems. The autosomal recessive disorder is the most common lethal inherited
disease in the Caucasian population and affects more than 1 in 3000 live births.
(3) The current median age of survival is 36.9 years of age, with affected males
typically living longer than affected females. (3) Diagnosis of CF is made by
evidence of clinical manifestations of CF in at least one organ system and
evidence of abnormal chloride secretion: an elevated sweat chloride (>60
mmol/L) on two occasions, presence of two disease causing mutations or an
abnormal nasal potential difference. While there are over 1,400 mutations in the
CFTR gene reported to cause CF, the most common mutation, F508 is a deletion
of the three nucleotides encoding phenylalanine at position 508. This mutation
accounts for over two thirds of CF cases worldwide and 90% of the cases in the
United States. (4)
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CF is caused by defective CFTR mediated chloride transport which causes
increased sodium and water absorption across epithelial cells and results in thick
viscous secretions in the pancreas, lung, liver, intestine, reproductive tract and
dermis. (5) Clinical manifestations of CF are recurrent respiratory infections,
pancreatic enzyme insufficiency, and elevated sweat chloride levels. Respiratory
manifestations occur in nearly 90% of homozygous patients who survive infancy.
Increased airways secretions caused by defective chloride secretion causes
decreased muco-cilliary function and defective clearance of the airways. As a
result, CF patients become colonized at an early age with pathogenic bacteria,
often Staphylococcus aureus and Pseudomonas aeruginosa. Patients develop a
persistent chronic cough, hyperinflation of the lungs, and pulmonary function
tests demonstrate obstructive airway disease. As the disease progresses, chronic
bronchitis is accompanied by malaise, anorexia, weight loss and digital clubbing.
Typically, CF patients ultimately succumb to complications related to their
pulmonary disease. (5-6)

Due to the multi-system clinical manifestations of the disease, treatment
regimes for CF patients typically involve a team of specialists including
pulmonary, endocrine and nutritional specialists.

The primary goal of CF

treatment includes maintaining lung function, controlling respiratory infections,
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clearing mucus from the airways and administering nutritional therapy to offset
pancreatic insufficiency.

Acute pulmonary exacerbations are often treated at

home but frequently require hospitalization.
physical

therapy,

postural

drainage,

Current therapies include, chest

inhaled

bronchodilator

treatment,

administration of Dornase alfa and inhaled and intravenous antibiotics. (6-7) Gene
therapy, correction of abnormal protein folding, improvement of endogenous ion
channel function and induction of alternate channels are some of novel
therapeutic strategies for CF that are being explored with variable success in
clinical trials. (6-7)

Cystic Fibrosis Transmembrane Conductance Regulator

CFTR is a phosphorylation dependent epithelial chloride channel located
in the apical membrane of epithelial cells in the lungs, liver, pancreas, digestive
tract, reproductive tract and skin. (5-9) The identification of the primary sequence
of CFTR was made in 1989 and CFTR was classified as a part of the ATP binding
cassette (ABC) transporters, traffic ATPases that use the energy from ATP
hydrolysis for transport. (13-14) The complete structure of the CFTR protein has
not yet been experimentally determined by X-ray crystallography largely because
the significantly hydrophobic trans-membrane regions are difficult to crystallize.
Currently only low-resolution structures of the several domains of the protein
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exist (15)).

CFTR contains
c
fivve domains, membranee spanning domains (M
MSD1

and MSD
D2) each with six trans-memb
t
brane helicees, two nuucleotide-biinding
domains (NBD1 andd NBD2), annd one reguulatory domain (R). Thhe two mem
mbrane
he NBDs an
nd the R doomain.
spanning domains arre separatedd and connected by th
b
andd hydrolysis at the
The transsport of ionss is thought to be driveen by ATP binding
NBDs which
w
causees dimerizaation of thee NBDs annd openingg of the chhannel
forming helices
h
(6). Regulation of CFTR
R mediated chloride
c
traansport occuurs by
modificattion of the R domain th
hrough cycllic-AMP deependent adddition or rem
moval
of phosph
hate groups. (1, 11) (Fiigure 1)

Figuree 1: Model shhowing the prroposed
domainn

structurre of CFTR. MSD,

membrrane-spanningg

domain;

nucleottide-binding

domain;

regulattory

PKA,

domain
n;

NBD,
R,
cAMP-

dependdent protein kiinase. (1)

P
n
CFTR meediated Ion Permeation

CF
FTR is onee of the onlly ABC traansporters known
k
to bee an ion channel.
Thus, thee study of CFTR’s ch
hannel function provid
des a uniqu
ue glimpse of
o the
ABC trannsporter mecchanism.
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Ion permeation is influenced by the presence of charged amino acid side
chains at the entrance of the channel pore (16). These specific residues attract
oppositely charged ions, which increase the effective local concentration, while
also repelling ions of similar charge. Site directed mutagenesis studies have been
used to identify the role of positive charged residues in ion conductance (17-18).
Functional evidence suggests that permeant anions bind to several discrete sites
within the CFTR channel pore (19-24). These binding sites may be involved in
attracting chloride ions into the CFTR pore (21) and in coordinating ion-ion
interactions that are necessary for rapid ion movement through the pore (24-26).

Specific inhibitors of the CFTR channel have been employed as tools to
investigate further the role of key amino acids in the channel pore. Chloride ion
binding sites within the pore may also be binding sites for small molecules that
occlude the pore and thus inhibit chloride transport. (25, 30-31) Several organic
anions have been demonstrated to occlude and inhibit chloride transport,
including glibenclamide, a sulfonourea (31, 34-35), CFTRinh-172 a thiazolidone
(36-39), and GlyH-101, a glycine hydrazide (40). Glibenclamide and GlyH-101
are thought to act as open channel blockers: glibenclamide acting from the
internal membrane surface and GlyH-101 from the external surface. CFTRinh172 is thought to bind at the R domain and does not act as an open channel
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blocker. (37) Initial studies suggest that CFTRinh-172 acts optimally during the
open state of the channel. (36-39) However, despite numerous site-specific
mutagenesis studies, the location and number of those inhibitor binding sides
remain unclear (30, 43-46).

An important limitation of site directed mutagenesis studies is that
manipulation of the amino acid sequence may cause disruption of important
secondary or tertiary structural relationships thus causing inaccurate conclusions
regarding changes in protein function observed or relative importance of mutated
amino acids. Cross species comparison studies serve as a powerful method to
analyze structure and function relationships (41-42, 47-48). The evolutionary
differences in amino acid sequences that arise over time and the conservation of
specific motifs in different species help to define the functional significance of
specific amino acids without the limitations of site directed mutagenesis.

Statement of Purpose

Several years ago, members of our lab observed profound differences in
the response of shark and human CFTR in response to three thiol-reactive
substances: mercury, zinc and glutathione. Site-specific mutations introduced at
shark unique cysteines in human CFTR revealed restoration of sensitivity to
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mercury mediated inhibition only observed in shark. (41-42) At this time, our lab
also observed that the novel CFTR specific inhibitor, CFTRinh-172, did not
inhibit CFTR mediated chloride secretion in short circuit current studies of shark
rectal gland tissues monolayers and in perfusion studies of the intact shark rectal
gland. These preliminary experiments prompted me, several years ago, to explore
the apparent species differences between shark and human CFTR in response to
CFTRinh-172 using two-electrode voltage clamping of Xenopus laevis oocytes. I
discovered that shark indeed was not sensitive to the significant inhibition of
conductance seen in the human ortholog of CFTR. (49) Realizing that CFTRinh172, glibenclamide and GlyH-101 may all inhibit chloride permeation through
interactions with the pore, my work has been expanded to study the inhibition of
all three CFTR specific inhibitors on four species of CFTR: shark, human, pig and
killifish. The purpose of this work was to explore the pharmacologic profiles of
these CFTR specific inhibitors across several species to elaborate structural and
functional relationships.

Materials and Methods

This student participated in the shark rectal gland perfusion studies, the
measurement of short circuit current, the synthesis of human and shark CFTR
cRNA, the harvesting and injection of Xenopus laevis oocytes, and initial studies
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of CFTR specific inhibitor, CFTRinh-172, on shark and human CFTR.

Other

colleagues in the lab, specifically Klaus and Max Stahl carried out additional
studies in pig and killifish CFTR with the multiple inhibitors.

In vitro perfusion of shark rectal glands.
Rectal glands were obtained from either sex of dogfish sharks, Squalus
acanthias, weighing 2-6 kg. Glands were removed and cannulae were placed in
the single artery, vein and duct as described previously (33). Glands were placed
in a glass perfusion chamber at 15°C equilibrated with running seawater. Glands
were perfused with an elasmobranch Ringer's solution (270mM NaCl, 4mM KCl,
3mM MgCI2, 2.5 mM CaCi2, 1 mM KH2PO4, 8mM NaHCO3, 350mM urea,
5mM glucose, and 0.5 mM Na2SO4) (all from Sigma Chemical Co., St. Louis,
MO) and equilibrated to pH 7.5 by bubbling with 99% 02 and 1% CO2. The
glands were perfused with shark Ringers solution for thirty minutes to reach basal
levels of chloride secretion (250µEq/h/g). Forskolin and IBMX were added to
the solution at 1µM and 100µM respectively. Chloride secretion was measured in
1-min intervals. After twenty minutes of stimulated secretion, 10µM CFTRinh172 was added to the perfusion solution for thirty additional minutes (50-80min)
and then removed. Measurements of duct flow were made at 10-min intervals in
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all experiments. Results are expressed as micro equivalents of chloride secreted
per hour per gram wet weight (μEq/h/g)p ±SEM.
Primary Cell Cultures of Shark Rectal Gland Tubules.

Primary cultures of shark rectal gland epithelial cell monolayers were
prepared per a protocol previously described (43). Rectal glands were excised
under sterile conditions, sliced horizontally into 2-3 mm sections, and minced into
a slurry with two sterile scalpel blades. The mince was transferred into a 50 ml
conical tube and washed 3x with 20 ml of sterile shark Ringer’s. The mince was
suspended in a collagenase solution (0.2% in 30 ml of sterile shark Ringer’s) and
incubated at 25˚C for 1 hour under constant agitation.

At the end of the

incubation, the suspension was washed with sterile shark Ringer’s by
centrifugation at 200xg at 4˚C for 45 seconds. The supernatant was discarded and
the pellet was re-suspended in 20 ml of sterile shark Ringer’s. The digested
mince was agitated to release the tubules into the supernatant. The suspended
tubules were harvested and kept on ice. Suspension, agitation, and harvesting of
the tubules were repeated two more times. The tubules were next washed and
suspended in 20 ml of sterile shark Ringer’s, from which two 1 ml aliquots were
removed to determine the total yield by wet weight. Average yields were 250-500
mg wet wt/gland. The tubules were then suspended in a medium composed of
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Dulbecco's Modified Eagle's Medium/Ham's F-12 (15 mM HEPES, 3.9 mM
CaCl2, 2.5 mM MgCl2, 300 mM urea, 94 mM NaCl, 150 mM trimethylamine
oxide, 21 mM NaHCO3, 10 ml/l penicillin/streptomycin (10000 U x 10 mg-1 x ml1

), 10 ml/l ITS+, and 50 ml/l Nu-Serum). Tubules, at a density of ~10 mg/ml,

were seeded onto 1.2 ml rat tail collagen gels (Cohesion Technologies) in 35 mm
dishes supported with 150 µm nylon mesh. The tubules were allowed to grow to
confluence at 18°C under 95% O2 and 5% CO2, typically within 10-14 days. The
nylon mesh containing the monolayer of cells was excised from the petri dish
using a sterile scalpel blade and mounted in an Ussing chamber. Both the apical
and basolateral sides of the monolayer were bathed with shark Ringer’s
containing 5 mM glucose at pH 7.5.

Measurements of Transepithelial Chloride Transport as Short Circuit Current
(Isc) in Primary Culture Monolayers: inhibition with CFTRinh-172 and GlyH101
Confluent cultures were mounted in a conventional Plexiglas Ussing
chamber with an aperture of 0.28 cm2. Both hemi-chambers were independently
perfused by gravity flow at room temp (20-22˚C) with shark Ringer’s solution and
95% O2 - 5% CO2. Trans-epithelial voltages were measured with an Iowa dual
voltage clamp (model 710C) and agar bridges connected to calomel electrodes
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using methods previously described (43-44). The bridges were filled with shark
Ringer solution and were positioned approximately 1 mm from the apical and
basolateral surfaces of culture.

Trans-epithelial resistance was measured by

applying bipolar current pulses every 50 seconds.

The voltage clamp

administered current via agar bridges linked to external Ag-AgCl electrodes.
Short circuit current (Isc), or net electrogenic chloride secretion (43), was
measured by determining the current necessary to clamp the spontaneous transepithelial voltage to 0 mV.

Inhibition by CFTRinh-172 and GlyH101 was

determined by the ratio of Isc measured at the peak of stimulation (1µM
Forskolin) and Isc at the highest concentration of the inhibitors. Results are
expressed as microampere per cm2 (µA/cm2) ± SE.

To study GlyH-101, the organic compound was added after steady state
conditions were reached at concentrations of 30, 60, 90 and 120µM to the
mucosal side of the monolayers. The study of CFTRinh-172 was similar to that
of GlyH-101.
Synthesis of hCFTR, pCFTR, kfCFTR, and sCFTR cRNA:

All CFTR orthologues were cloned into T7 expression vectors. Human,
shark and pig CFTR sequences were in pcDNA3.1, whereas kfCFTR was in
pGEMTeasy expression vector. The vectors were grown up in 150ml cultures of
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TOP10 electrically competent E. coli (Invitrogen, Crlsbad, CA) and subsequently
isolated using Pure Yield Maxiprep Systems (Promega, Madison, Wisconsin).
The clones were whole length sequenced to confirm the integrity of the CFTR
ORFs. 12µg CFTR DNA was linearized with XhoI and purified by PCR
purification (Qiagen, Alameda, CA). Capped cDNA was synthesized using T7
RNA polymerase and in vitro transcription following the instructions of T7 in
vitro transcription system (Ambion, Austin, TX). The reaction products were
precipitated using lithium-chloride precipitation and tested with the Agilent
Bioanalyzer system (Agilent, Santa Clara, CA). (50)

Oocyte preparation and expression of hCFTR, pCFTR, kfCFTR and sCFTR.

Mature female Xenopus laevis (Xenopus I, Dexter, Michigan) were
anesthesized in a 0.15 % cold solution of tricaine for 20min, and several ovarian
lobules were removed under sterile conditions through an abdominal incision per
the protocol approved by the Yale University Institutional Animal Care and Use
Committee. The ovarian lobules were manually dissected in smaller pieces and
kept in calcium free ND96 (96mM NaCl, 1mM KCl, 1mM MgCI2·6H2O, 5mM
HEPES (1/2 Na) equilibrated to pH 7.5) (all from Sigma Chemical Co., St. Louis,
MO). Oocytes were de-folliculated by incubating in a 2.5mg/ml solution of type I
collagenase for 2 hours and subsequently treating with a hypertonic potassium
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phosphate solution. Mature stage V and VI oocytes were selected and stored in
modified Barth solution (MBS) (88mM NaCl, 1mM KCl, 2.4mM NaHCO3,
0.82mM MgSO4·7H2O, 0.33mM Ca(NO3)·4H2O, 0.41mM CaCl2·H2O, 10mM
HEPES (1/2 Na) and 1% Penicillin/Streptomycin equilibrated to pH 7.4) (all from
Sigma Chemical Co., St. Louis, MO) at 18°C. The oocytes were injected with 15ng of cRNA / 50nl or an equivalent volume of water and stored for 1-2 days in
MBS at 18°C. (50)
Two electrode voltage clamping: inhibition of hCFTR, pCFTR, kfCFTR and
sCFTR with CFTRinh-172, GlyH101, and Glibenclamide.
Electrophysiological recordings were performed 1-2 days after injection of
the cRNA. Electrodes were pulled on a micropipette puller (Sutter Instruments,
Novata, CA), the electrodes were filled with 3M KCl and had input resistances
between 0.6 and 1.3 MΩ.

During two-electrode voltage clamping recording,

current-voltage (I-V) curves were obtained by clamping the voltage over a ramp
from -120 to +60 mV at a rate of 100mv/s with the use of a two-electrode voltage
clamp (TEV-200, Dagan Instruments, Foster City, CA). After correcting for
capacity currents, reversal potentials were determined and conductances were
calculated over a range of ±20mV. During the experiment, the oocytes were
perfused with calcium containing ND96 (ND96 in addition of 1.8mM
CaCl2·H2O). I-V ramps were taken under basal conditions and during stimulation
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by forskolin (10µM) and IBMX (1mM). Once the stimulation reached a steady
state, the different inhibitors were added beginning with the smallest inhibitor
concentration. Once currents with one concentration of the specific inhibitor
reached a steady state, the next higher concentration of the same inhibitor was
used. IBMX and Forskolin were used continuously throughout stimulation and
inhibition. Washout was performed with ND96 alone. The inhibitors used were
CFTRinh-172 (Sigma, Cystic fibrosis therapeuticals), GlyH-101 (Cystic fibrosis
therapeuticals) and Glibenclamide (Sigma) at concentrations of 5, 10 and 20 µM.
The maximum dose of 20µM was used for two reasons: first at greater
concentrations of drug used, solubility became a factor and secondly, 20 µM was
near maximum inhibition demonstrated in all species. In all experiments
inhibition was determined by the ratio of the conductance measured at steady state
conductance of IBMX and Forskolin mediated stimulation and the conductance
obtained at the steady state of inhibition by the specific dose of the specific
inhibitor. Data was analyzed with pCLAMP software. Results are expressed as
micro Siemens (µS) ± SE.
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Results
Measurem
ments of Trrans-epithellial Chloridde Transport as Shortt Circuit Cuurrent
(Isc) in Prrimary Cultuure Monolaayers: Inhibbition with CFTRinh-17
C
72 and GlyH
H101
GlyH--101: Chlorride secretioon.

GlyH-101
G
siggnificantly inhibits sCF
FTR-mediatted secretio
on of short ccircuit
current (441.3 ± 3.0 % inhibitionn). Individuual experimeents (resultss not shownn here)
demonstrrate that thhe additionn of 10µM
M CNP, 200µM milrinnone and 10µM
forskolin cause the Isc to inccrease and reach stead
dy state acctivation aftter 50
minutes with
w a steaddy state currrent of aboout 50 µA. After the addition of GlyHG
101 (30, 60, 90 andd 120µM) the
t current decreases in
i a dose specific stepp-wise
fashion too currents below 30µA
A. (Figure 8))

70
60

% Inhibition

50
40
30
20
10
0
CFFTRinh‐172

Glibeenclamide

GlyH
H‐101

Figure 2: In
n primary culltured SRG eppithelial cellss, chloride traansport, measu
ured as Isc was
w first

stimulated by secretagoggues (forskoliin 10 µM andd IBMX 100 µM) and Isc increased from base
line valuess of 9.4 ± 5.7
5

µA/Cm
m2 to 69 ± 16.5

µA/C
Cm2 to inhibitors (CFTRinnh-172,
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glibenclamide, and GlyH-101 were then added and the mean % inhibition was calculated (n=4-6
per group).

Glibenclamide: Chloride secretion

Individual experiments demonstrate a modest inhibition of chloride
secretion by glibenclamide when compated to gly-H inhibition. (15.8 +/- 16.5 %
inhibition of Isc)

CFTRinh-172: Chloride secretion.

Individual experiments demonstrate activation of Isc from basal values
after the addition of 10µM Forskolin and 1µM VIP. Steady state stimulation
occurs after 40 min with Isc currents typically greater than 80 µA. The addition
of GlyH-101 to this activating cocktail again causes a similar decrease in current
to values below 60µA as was demonstrated in the previously described
experiments. However, the addition of 50µM CFTRinh-172 to the perfusate does
not cause a further decrease in short circuit current but rather the current is
observed to remain at the steady state currents observed after the addition of
GlyH-101.

Figure 2 demonstrates the percent inhibition in shark CFTR

mediated chloride secretion by GlyH-101 (n=4) and CFTRinh-172 (n=3).
CFTRinh-172, in contrast to GlyH-101, does not inhibit sCFTR secretion short
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circuit current (CFTRinh-172; 2.5 ± 0.15 % inhibition, GlyH-101; 56.5 ± 6.55749
% inhibition).
Conductance of hCFTR, kfCFTR, pCFTR, sCFTR and un-injected and water
injected controls under basal and stimulated conditions.
The conductance of oocytes was measured 2-3 days post injection in 109
oocytes injected with hCFTR (n=20), kfCFTR (n=25), pCFTR (n=21), sCFTR
(n=15), water (n=12) and un-injected (n=12). Human CFTR, kfCFTR, pCFTR
and sCFTR had basal conductances of 11.9 ± 1.4 µS, 20.5 ± 1.9 µS, 13 ± 3.3 µS
and 6.7 ± 1.3 µS respectively. Un-injected and water injected control oocytes had
a significantly lower baseline conductance of 7.2 ± 1.2 µS and 6.2 ± 0.6 µS,
respectively (P  0.05) compared with baseline conductances of hCFTR, kfCFTR,
pCFTR and sCFTR.

Because the aim of the study was to study the effects of CFTR specific
inhibitors after activation of CFTR, it was important to establish comparable
steady state conductances amongst the four species of CFTR. After the addition
of 10µM forskolin and 1mM IBMX to the perfusate, hCFTR, kfCFTR, pCFTR
and sCFTR had similar steady state conductances (206 ± 21.9 µS, 218.7 ± 14.3,
160.1 ± 29.5 µS and 160.7 ± 34 µS). While the steady state activated
conductances of hCFTR and kfCFTR appeared larger than those of pCFTR and
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sCFTR, these
t
obserrved differeences were not statistiically significant and likely
were secoondary to natural
n
diffferences in oocyte batcches and diifferences due
d to
daily con
nductance variability.
v

njected
In the control un-iinjected andd water inj

oocytes, the conducctance afterr stimulationn with IBM
MX and forrskolin rem
mained
o the conducctances meaasured at baaseline (5.9 ± 1.6 µS and
a 5.8 ± 0.55 µS).
similar to
The basall and stimullated conduuctances in control
c
oocyytes were siignificantly lower
than thosse of all speecies of CF
FTR under both basal and steadyy state stimuulated
conditionns (P  0.001). (Figure 3)

Figure 3: Coonductances of Xenopus oocyttes expressing hCFTR
h
(n=20), kfCFTR (n=25
5), pCFTR (n=221),
sCFTR (n=15) and uninjectted (n=12) or water
w
injected (nn=12) oocytes as
a negative con
ntrols. Un-injeccted
and water injjected control oocytes
o
had a significant
s
loweer baseline cond
ductance and a highly significcant
lower steady
y state conductance than hCF
FTR (P 0.05 and  0.001, respectively). The baseline and
steady state conductances
c
off the four species did not diffeer significantly. Conductance is
i measured on the

Comparisson of C
CFTR speccific inhibiitors, CFT
TRinh-172, GlyH101 and
Glibenclaamide acrosss species off CFTR meddiated cond
ductance.
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The conductance changes over time are demonstrated in representative
experiments in Figure 4. In all species of CFTR, stimulation with forskolin and
IBMX resulted in a prompt increase in conductance, which reached a steady state
after 20-30 minutes.

The addition of inhibitors to the perfusate consequently

caused a decrease in conductance.

The dose response of the CFTR mediated

conductance is observed as a stepwise decrease in conductance as increasing
concentrations of the specific inhibitors are added to the perfusate. In contrast to
the similarities observed across species of CFTR after stimulation by forskolin
and IBMX, the response to each inhibitor was different across species.
The I-V relationships for the oocytes are demonstrated in Figures 5b and 6b.
Throughout all experiments, all species of CFTR injected oocytes exhibited
similar linear I-V relationships. After the addition of forskolin and IBMX, the
reversal potentials depolarized toward the resting potential of chloride.
Similarly, after the addition of the various inhibitors that caused inhibition of
CFTR mediated anion conductance, the reversal potential re-polarized toward
basal values.
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CFTRinh-1
172: sCFTR
R is unrespon
nsive to CF
FTRinh-172
A dose
d
responsse comparisson was maade across species
s
of CFTR
C
with 5, 10,
and 20µM of CFTRinnh-172. CFT
TRinh-172 inhibited hCFTR
h
sign
nificantly (115.9 ±
M, 39.8 ± 3.7% at 10µM
M and 61.2 ± 3.2% at 20µM).
2
How
wever,
2.9% inhibiition at 5µM
a less prom
minent respoonse to CFT
TRinh-172 was observved in kfCF
FTR and pC
CFTR,
particularlyy at higher doses (43.5 ± 5% aand 20.6 ± 5.1% inhiibition at 220µM,
respectively
y) (Figure 5A)
5

Figure 5: Coomparison of thhe effects of CFT
TRin-172 on CF
FTR species.
A: Summary
y of % Inhibitiion of h-, kf-, pp and sCFTR with
w 5, 10 and 20 µM of CFT
TRinh-172. sCF
FTR
was almost unresponsive
u
too CFTRinhib172
2 (1.5 ± 0.2% inhibition
i
at 5µ
µM, 5 ± 0.8% at
a 10µM, 8 ± 1..4%
at 20µM). The
T absence of inhibition of sCFTR
s
by CFT
TRinh-172 is highly
h
significaantly (P=0.001 for
5µM, P=1.5xx10-5 for 10µM
M and P=2x10-77 for 20µM) com
mpared to hCFT
TR.

Interesttingly, sCFT
TR was alm
most compleetely unresponsive to CFTRinh-17
C
72 (1.5
± 0.2% inhibition at 5µ
µM, 5 ± 0.88% at 10µM
M, 8 ± 1.4% at 20µM). The inhibittion of
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sCFTR by CFTRinh-172 is highly significant (P=0.001 for 5µM, P=1.5*10-5for
10µM and P=2*10-7 for 20µM) when compared to hCFTR. (Figure 5a)
I-V plots for both species are shown in Figure 5b and demonstrate similar
currents between between human and sCFTR at basal and stimulated conditions and
different responses in current after addition of CFTRinh-172 to the perfusate. I-V
ramps were taken at the end of each of the following conditions: baseline perfusion
Figure 5: Comparison of the effects of CFTRin-172 on
CFTR species.
B: Representative I-V plots from oocytes expressing hand sCFTR. Human- and sCFTR show similar currents
at baseline and after stimulation. However, they differ
significantly in the currents they exhibit after inhibition
with CFTRinhib172.

with frog ringer solution until the
conductance reached a baseline steady
state, stimulation with forskolin (10µM)
and IBMX (1mM) until conductance
reached a new steady state and inhibition
with CFTRinh-172 (20µM).
To further explore the findings that sCFTR is unresponsive to CFTRinh172, in vitro inhibition was examined using both isolated shark rectal glands in
perfusion studies and by measurement of short circuit current (Isc) in primary
culture monolayers of rectal gland tubular cells. Perfusion studies confirmed that
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CFTRinh–172 had no effect on chloride secretion in the shark rectal gland (Figure
6). The effects of CFTRinh–172 on chloride secretion in rectal gland monolayer cells
were consistent with the perfusion studies. Addition of 1, 5 and 10 µM CFTRinh–
172 to 1 µM forskolin and 100 µM IBMX stimulated cells showed no inhibition in
four experiments (results not shown).
Forskolin (1M) + IBMX (100M)
CFTR-172 (10M)

Chloride Secretion (µEq/h/g)

3 50 0

3 00 0

Forskolin +IBMX

2 50 0

C
2 00 0

1 50 0

1 00 0

50 0

0
0
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20
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Figure 6: Chloride secretion in perfused shark rectal glands with 1 µM forskolin and 100 µM IBMX added
to the perfusate. CFTRinh–172 (10 µM) was added from 50-70 min in experimental studies (n=5) and
effects were compared to controls (n=18). Values are mean  SEM. Forskolin and IBMX are squares,
CFTRinh-172 are diamonds.

Glibenclamide: pCFTR is unresponsive to Glibenclamide

Similar to the experiments with CFTRinh-172, we compared the dose
response of the four different CFTR species to glibenclamide (5, 10 and 20µM).
Glibenclamide inhibited hCFTR significantly (29.7 ± 3.7% inhibition at 5µM, 44.6
± 1.9% at 10 µM and 61.3 ± 3.7% at 20µM). Unlike CFTRinh-172, sCFTR was
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responsive to glibenclamide (30.2 ± 4.5% inhibition at 5µM, 40 ± 8.6% at 10 µM
and 52.2 ± 7.7% at 20µM) (Figure 7a). Similar to CFTRinh-172, kfCFTR was also
less.

Figure 7: Comparison of the effects of Gibenclamide on CFTR species.
A: Summary of % Inhibition of h-, kf-, p- and sCFTR with 50, 100 and 200 µM of Glibenclamide.
Importantly, % inhibition of pCFTR by Glibenclamide (4.9 ± 1.7% inhibition at 5µM, 10.2 ± 4.2% at 10
µM and 12.8 ± 4.2% at 20µM) was highly significant at all concentrations studied (p<0.001) when
compared to human.

Interestingly,

pCFTR

was

highly

significantly

unresponsive

to

glibenclamide (4.9 ± 1.7% inhibition at 5µM, 10.2 ± 4.2% at 10 µM and 12.8 ±
4.2% at 20µM, P < 0.001 in all concentrations) in comparison to human.

I-V plots for both species are shown in Figure 7b and demonstrate
similar currents between human and pCFTR at basal and stimulated conditions and
different responses in current after addition of glibenclamide to the perfusate.
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These results are supported by recently reported observations in short circuit
current studies with human, pig, ferret and mouse that pCFTR is less sensitive than
hCFTR to glibenclamide (48).

Figure 7: Comparison of the effects of
Glibenclamide

on

different

CFTR

species.
B:

Representative

I-V

oocytes expressing h-

plots

from

and pCFTR.

Human- and pCFTR show similar
currents

at

stimulation.

baseline

and

after

However,

they

differ

significantly in the currents they exhibit
after inhibition with Glibenclamide.

GlyH-101: All species are responsive to GlyH-101
In contrast to CFTRinh-172 and glibenclamide, hCFTR, kfCFTR,
sCFTR and pCFTR are all responsive to GlyH-101. This inhibition is particularly
evident at the highest concentration used (20µM). Shark, kfCFTR and pCFTR are
inhibited more by GlyH-101 than hCFTR (hCFTR: 47.8 ± 4.7%; kfCFTR: 58.1 ±
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3.9 %; pCF
FTR: 80.2 ± 3.6%; sCF
FTR: 70.1 ± 3.8 %). Shark and pig’s sensitivitty was
highly signnificant at 20µM (P < 0.001). Additionally
A
y, sCFTR shows a pprompt
response to
o GlyH-1011 inhibition at the low
west concenttration of GlyH-101
G
sttudied
(49.3 ± 3.3 % in contraast to 20.2 ± 3.8 % withh hCFTR). (Figure 8)

Figure 8: Coomparison of thhe effects of GlyyH-101 on differrent CFTR speccies.
Summary off % Inhibition of
o h-, kf-, p- and sCFTR with 5, 10 and 20 µM
µ of GlyH-1001. All species are
responsive to
o GlyH-101. At
A 20µM, kfCF
FTR, sCFTR annd pCFTR aree significantly more
m
inhibitedd by
GlyH-101 than the human isoform
i
(hCFTR
R: 47.8 ± 4.7%
%; kfCFTR: 58.1 ± 3.9 %; pCF
FTR: 80.2 ± 3.66%;
sCFTR: 70.11 ± 3.8 %). Shark CFTR is
i highly signifficantly more sensitive (P < 0.001) to GlyyH101mediatedd inhibition of chloride current than hCFTR att all concentratiions studied andd pCFTR is higghly
significant att 20µM (P < 0.0001).

Discussion
n

Reverse Phharmacologyy of CFTR

Thee “reverse pharmacolog
p
gy” methodd of analyziing the relaationship beetween
structure an
nd functionn of ion chaannels is deependent onn the use of
o pharmacoologic
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agents that are known to interact with and block the ion channel. (58) These small
molecule pore blocking agents are used as probes of the ion pore to analyze the
effects of mutagenesis on blocking behavior. The term “reverse pharmacology”
was coined because the known structure of the inhibitor was used to investigate the
unknown contours of the channel pore. (32, 53) Our study design uses this concept
of reverse pharmacology to analyze the behavior of known inhibitors on several
species of CFTR rather than in mutagenesis studies. The benefit of using cross
species analysis is that we avoid the limitations of mutagenesis studies, wherein
single amino acid changes disrupt channel function through global changes in the
secondary or tertiary structure of the protein.

We studied the effects of three inhibitors on four isoforms of CFTR, each
with varying sequence identity to the human isoform and each with distinct
sequence motifs. The pharmacologic profiles of each CFTR isoform would be
expected to elucidate structure and functional relationships.

Charged Vestibule Model of CFTR

The “charged vestibule model”, described by Green and Andersen in 1991,
proposed that the general features of channel structure are the result of evolutionary
pressure due to the limitations on the rate of ion conduction imposed by diffusion.
(16) They reviewed theoretical and experimental data, which suggested that the
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rapid ion translocation across the thickness of a biological membrane could only be
possible if the narrow region of the pore responsible for selectivity and binding, is
flanked by vestibules designed to increase the capture radius at the channel mouth,
and to concentrate permeable ions by electrostatic means. (21) This model is widely
used in the literature (17, 54) to explain structure-function relationships of CFTR.

Figure 9: The charged vestibule model of CFTR mediated chloride transport.

Site directed

mutagenesis studies have implicated several positively charged amino acids in the vestibules and
pore in the attraction and binding of chloride. (17, 21, 22, 28, 55-56) Experimental studies suggest
that GlyH-101 occludes the pore extra-cellularly and that glibenclamide occludes chloride transport
intra-cellularly. (31, 40) CFTRinh-172 may act on the R domain to inhibit chloride conductance.
(36-39)

The charged vestibule model proposes that the CFTR channel pore consists
of three regions: an outer vestibule, pointing towards the outside of the cell
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membrane, a narrow region, which is the rate limiting area of the selectivity filter
and an inner vestibule, that is opened towards the cytoplasm. (Figure 9)

Because CFTR is predominantly permeant to negatively charged chloride
ions, positive charges within the pore are theorized to promote the accumulation of
chloride and to create a conditioned environment adjacent to the rate-limiting
narrow section of the pore. Several site-specific mutagenesis experiments have
observed changes in conductance and current-voltage rectification secondary to
mutations made within the CFTR pore.

These observations suggested that

positively single charged residues are an essential part of the outer and inner
vestibules. Several permeant anion binding sites exist. The positive charges in the
outer vestibule are R334 and K335 in TM6 and R104 and R117 in extracellular
loop 1 and the positive charges in the inner vestibule are K95 and R303 in TM1 and
TM5. (17, 28, 55-56) These amino acids are considered important in drawing
extracellular and intracellular chloride anions respectively into the central narrow
pore region. The residues R347 and R352, both present in TM6 are a part of the R
domain but are theorized to be important in permeation, open state stability and
structural integrity. The residues, F337, T338 and S341 are present in the narrow
region of the pore and may play role in the rate limiting steps of anion permeation.
(21-22) As CFTR specific inhibitors GlyH101 and Glibenclamide are both
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negatively charged and the CFTRinh-172 is at least hydrophobic, these positively
charged amino acids important in chloride anion attraction and binding may also be
important binding sites for inhibition by small molecules. (40, 35) The negatively
charged inhibitors may therefore be competing with chloride anions for affinity and
binding within the CFTR pore providing a mechanism for occlusion and inhibition.
(Figure 10 )

CFTRinh-172: sCFTR and residues 347 and R352

We demonstrated in three experimental models, including, (1) two electrode
voltage clamping (TEVC) of Xenopus laevis oocytes, (2) short circuit current
studies in shark rectal gland tissue monolayers from primary tissue culture and (3)
intact shark rectal gland perfusions that sCFTR shows nearly no response to
CFTRinh-172.

TEVC studies further demonstrated that pig and kfCFTR are

significantly less responsive to CFTRinh-172 than hCFTR. Recent work provides
evidence that CFTRinh-172 interacts directly with CFTR’s R domain at a region
that is important to formation of the channel. (37) Mutations introduced at R347
and R352 in TM6, replaced arginine with alanine, and demonstrated decreased
inhibitory potency in functional assays. (37)

Because of the observation that CFTRinh-172 has decreased potency of
inhibition in functional studies with pig and kfCFTR and almost no potency with
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sCFTR, we proposed that the amino acids identities at position 347 and 352 were
substituted with different amino acids, perhaps not neutral or less positively charged
than arginine. However, examination of the sequence alignment of these four
CFTR isoforms reveals positions R347 and R352 have perfect consensus. (Figure
10) This sequence conservation suggests that these two residues alone are not
sufficient to explain the mechanism of action of CFTRinh-172. Looking closer at
the amino acid sequence adjacent to R347 and 352, positions 349 and 356 and 357,
were less conserved across species. In human and pig, the non-polar amino acid,
alanine, are present at positions 349 and 357 and the polar residue tryptophan is
present at position 357. In shark and killifish, these non-polar and polar residues
are replaced with threonine and serine respectively, both with partial negative
charges. These partial negative charges may decrease the potency of CFTRinh-172
by decreasing the affinity of the polar organic compound to the adjacent positively
charged arginine residues. However, this does not explain the observed decreased
potency of the inhibitor on pCFTR as the residues in this region are completely
conserved with its human isoform.

Glibenclamide: pCFTR and residues K95 and R303

The most striking difference in pharmacologic profiles demonstrated by
TEVC studies was that pCFTR mediated chloride conductance was completely
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unresponsive to glibenclamide and that kfCFTR showed decreased response when
compared to shark and hCFTR. This observation confirmed previously published
short circuit current studies that pig was unresponsive to inhibition by
glibenclamide. (48) Glibenclamide is thought to block the CFTR channel in a
complex mechanism by interacting with multiple binding sites with varying degrees
of affinity that is both voltage and pH dependent. Patch clamp studies suggest that
glibenclamide blocks CFTR by interacting with two sites within the channel pore
and one site that lies in the inner vestibule. (32) The amino acids K95 and R303
have been proposed to be important with glibenclamide’s interaction with the inner
vestibule. (34, 56) Therefore, we hypothesized that there may exist a speciesspecific difference in the amino acid sequence at K95 and R303 that accounts for
the differences in pharamacologic profiles observed in our TEVC studies.
However, examination of the amino acid sequence alignment of the four isoforms
demonstrates conservation of these residues suggesting that these residues are not
solely responsible for the interactions of glibenclamide with the channel pore. We
again examined the amino acid sequence alignment adjacent to K95 and R303. In
human and sCFTR the non-polar residues alanine and leucine occupy position 96
and 102. These positions in the killifish isoform are occupied by threonine and
serine respectively, which have partial negative charges.

This could, again,

theoretically explain the differences in inhibitory profile observed with kfCFTR.
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However, the residues K95 and R303 are conserved in pCFTR.

The absent

inhibition of pCFTR mediated conductance may be due to differences in sequence
homology between the CFTR isoforms at the two other suggested sites that
glibenclamide is theorized to interact with in the channel pore.

GlyH101: Residues R334, K335, R104 and R117

All four CFTR isoforms were rapidly and significantly responsive to GlyH101 mediated inhibition of chloride conductance. Furthermore, shark and pCFTR
were comparatively more responsive to GlyH-101 inhibition than human and
kfCFTR, which is in contrast to shark and pCFTRs relative decreased sensitivity to
CFTRinh-172 and glibenclamide.

GlyH-101 is like glibenclamide, an open

channel blocker, but GlyH-101 is unique because it acts by a novel external pore
occluding mechanism.

Compared with both CFTRinh-172 and glibenclamide,

GlyH-101 is >50 fold more water-soluble and is rapid and reversible suggesting it
acts at the extracellular face of the channel. The positively charged residues R334,
K335, R104 and R117 have been proposed to be essential to GlyH-101’s interaction
with the outer vestibule. (28, 40, 57) These four residues are conserved in all four
species of CFTR studied. As all four isoforms of CFTR are sensitive to GlyH-101
inhibition, the conservation of these four residues may confirm their importance in
GlyH-101 function.

Examination of the amino acid sequences adjacent to the
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positively charged arginine and lysine residues reveals that at position 115 in
hCFTR, a strongly negatively charged glutamic acid residue resides, where as in
shark and pig CFTR, position 115 is occupied by the neutral residue alanine. Shark
CFTR furthermore has a positively charged residue at position 113 which is not
present in the other isoforms. Shark CFTR demonstrated rapid inhibition by GlyH101 even at the smallest concentrations studied. The replacement of a negatively
charged residue with a neutral residue, and the addition of a positively charged
residue, at region thought to be important for the attraction and binding of the
negatively charged GlyH-101 may explain the potency of this particular inhibitor
when interacting with shark CFTR.
Figure 10: Amino Acid Sequence Alignment of Human, Pig, Shark and Killifish CFTR: Conserved residues that are suggested
to be important for CFTR specific inhibitor binding are in bold. Green amino acids are proposed binding sites for CFTRinh
172, red are for glybenclamide, and yellow for glyH-101. The sequence alignment was made using ClustalW2 Alignment and
Biological Workbench. Key: “*” means that the residues in the column are identical in all sequences in the alignment. “:”
means that conserved substitutions have been observed. “.” means that semi-conserved substitutions are observed.

Human

MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRE 60

Killifish

MQKSPVEDANFLSRFVFWWITPLLRKGFTKKLELTDVYKAPSFDLADTLSERLEREWDKE 60

Pig

MQRSPLEKASIFSKLFFSWTRPILRKGYRQRLELSDIYHISSSDSADNLSEKLEREWDRE 60

Shark

MQRSPIEKANAFSKLFFRWPRPILKKGYRQKLELSDIYQIPSSDSADELSEMLEREWDRE 60
**:**:*.*. .*::.* *

*:*:**: ::***:*:*: .* * ** *** ******:*

Human

LAS-KKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSI 119

Killifish

VVLAKGRPKLLKALARCFFLPFAFFGVLLYLGEASKTVQPQLSGRIIASFDPFHAAERSQ 120

Pig

LAS-KKNPKLINALRRCFFWRFMFYGIILYLGEVTKAVQPLLLGRIIASYDPDNKAERSI 119

Shark

LATSKKNPKLVNALRRCFFWRFLFYGILLYFVEFTKAVQPLCLGRIIASYNAKNTYEREI 120
:.

Human

* .***::** ****

* *:*::**: * :*:***

******::. :

**.

AIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQ 179
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Killifish

GYYLALGLGLLFTARFILLQPAIYGLHHLGMQIRIALFSLIYKKTLKLSSKVLDKISTGQ 180

Pig

AIYLGVGLCLLFIVRTLLLHPAIFGPHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQ 179

Shark

AYYLALGLCLLFVVRTLFLHPAVFGLQHLGMQMRIALFSLIYKKILKMSSRVLDKIDTGQ 180
. **.:** *** .* ::*:**::* :*:***:***:******* **:**:*****. **

Human

LVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAG 239

Killifish

LVSLMSAHLNKLDESLGLAHFVWITPLQCILCTGLIWELIEVNGFCALASLTLLGILQAW 240

Pig

LVSLLSNNLNKFDEGLALAHFVWIAPLQVTLLMGLLWELLQASAFCGLAFLVVLALFQAG 239

Shark

LVSLLSNNLNKFDEGVAVAHFVWIAPVQVVLLMGLIWNELTEFVFCGLGFLIMLALFQAW 240
****:* :***:**.:.:******:*:*

*

**:*: :

**.*. * :*.::**

Human

LGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKA 299

Killifish

LSLKMGPPRAQRAGLINRRLALTSEIVENIHSVKAYGWEEVMETIIKNIRQDEMTLTRKI 300

Pig

LGKMMMKYRDQRAGKINERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKA 299

Shark

LGKKMMQYRDKRAGKINERLAITSEIIDNIQSVKVYCWEDAMEKIIDDIRQVELKLTRKV 300
*.

*

* :*** *..**.:***:::**:***.* **:.**.:*.::** *:.****

Human

AYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQ 359

Killifish

GSLRYFYSASYFFSAILVIVSAIVPHALSNGIILRRIFTTASYCVVLRMTLTRQLPGSIQ 360

Pig

AYVRYFNSSAFFFSGLFVVFLSVLPYALLKGIMLRKIFTTISFCIVLRMAVTRQFPWAVQ 359

Shark

AYCRYFSSSAFFFSGFFVVFLSVVPYAFIHTIKLRRIFTTISYNIVLRMTVTRQFPSAIQ 360
.

*** *:::***.::*:. :::*:*: : * **:**** *: :****::***:* ::*

Modulation of Channel Gating

The unique interactions observed between the GlyH-101, CFTRinh-172 and
glibenclamide and different species of CFTR despite amino acid sequence
conservation in the charged vestibule and regulatory domains may also be explained
by the complex nature of species specific channel kinetics and by the binding
affinity or equilibrium dissociation constant of each inhibitor. The macroscopic
conductance Gj for ion j is given by:
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Gj = gj x N x Po

where is gj the individual conductance of each channel, N is the number of available
channels in a given membrane and Po is open probability of that channel. In our
studies, we assumed that the number of available channels measured during each
experiment did not affect the percent inhibition of maximal stimulation. We
furthermore, assumed that channel conductance, gj, did not differ between species
of CFTR and that the open probability of each channel were similar and that small
differences did not contribute to the macroscopic conductance measured. However,
identical Gj = gj x N x Po, do not necessarily imply identical gj, N or Po: for
example a small number of channels with a greater open probability may be equal
to a large number of channels with a low open probability. Several recent studies
have revealed single channel conductance differences between xenopus laevis,
human and shark CFTR: xenopus laevis CFTR demonstrates significantly greater gj
than the human and shark isoforms.

Furthermore single channel conductance

studies demonstrate differences between the open probabilities of CFTR isoforms.
A notably reduced Po of mouse CFTR was observed when compared with rodent
(59, 60) and human CFTR (61). The gating behavior of mouse CFTR has also been
observed to be dramatically different than human CFTR with differing patterns of
channel openings and closures. (61, 62) Glibenclamide, GlyH-101 and CFTRinh-
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172 are all open channel inhibitors (63, 40, 64) that act by presumably shortening
the open time but not the closed time of the channel. The rate of association and
disassociation of these inhibitors with their binding sites may be influenced by the
kinetics of opening and closing of each channel. Therefore, the individual channel
kinetic characteristics and the binding affinities of each inhibitor may influence the
macroscopic differences in conduction and inhibition observed.

Conclusion: Questioning the Single Amino Acid Binding Models.

In summary, we demonstrate in this study and confirm previously reported
observations (41, 40, 48) that cross species examination of the CFTR protein
reveals unique pharmacologic profiles for several CFTR specific inhibitors. These
distinct species differences cannot be explained by reverse pharmacology because
the proposed amino acids that these inhibitors interact with are uniformly conserved
across the species studied and thus cannot account for the differences in function
observed. This study suggests that the binding of the inhibitors with the channel
vestibule and pore is likely the result of a complex interaction involving multiple
amino acids at multiple sites. Ion transport is dependent on the unique matrix of
charged residues in the vestibules and pore, which create electrostatic potentials that
increase conductance by increasing the concentration of chloride. In this complex
picture of selectivity, the positioning of positively or partially charged residues is
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vital to channel function.

Therefore, the differences in inhibition demonstrated across diverse CFTR
species cannot be explained by simply targeting one amino acid for site-directed
mutagenesis. Rather, the potency of inhibitory actions of CFTRinh-172, GlyH-101
and gibenclamide on the CFTR molecule is dictated by the local environment and
the three dimensional structure of residues that form the vestibule and the chloride
pore and regulatory domain. The identity of the amino acids that play important
roles in binding and inhibition may not fully be understood until the crystal
structure of the CFTR protein is solved.
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